Navigation Links
Genta Restructures Operations to Focus on Priority Initiatives
Date:4/2/2008

Company to Seek Buyer for Marketed Product Ganite(R) Lloyd Sanders Assumes Chief Operating Officer Role in Consolidated Company

BERKELEY HEIGHTS, N.J., April 2, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced that the Company has restructured certain of its operations to conserve cash and focus on its priority oncology development operations. In March 2008, the Company received notice that its appeal of an adverse decision by the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) regarding its New Drug Application (NDA) for the use of Genasense(R) in patients with chronic lymphocytic leukemia (CLL) would not be reversed. While the Company is undertaking certain actions recommended by CDER, this decision precludes a commercial launch of Genasense during 2008, and accordingly the Company has reduced its workforce by 16 people, or approximately 30%.

"The highest priority for the Company is the timely completion of accrual and data readout from AGENDA, our ongoing Phase 3 trial of Genasense in patients with advanced melanoma", said Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Since these products address important patient needs and generate revenue for the Company, we will be maintaining our "named-patient" programs for Genasense and Ganite. However, given the delays in commercialization of our lead product, we have underinvested in our marketed drug, Ganite(R), and will be seeking buyers for that product. In other actions, we expect to file a complete response to FDA's clinical hold on tesetaxel, our new oral taxane, and we anticipate clinical presentations on both Genasense and G4544 -- an oral compound that reduces calciu
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Ophthalmic drug delivery technologies or ... endeavors as the anatomy, physiology and biochemistry of ... foreign substances. Ocular drug delivery technologies provide several ... minimal use of needles; also it enables high ... specific targeting within the ocular globe. On the ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
(Date:8/21/2014)... & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of JRC-LAMP-vax, ... Japanese red cedar pollen. Phase IC studies began this ... real solution to hay fever. , The Japanese red ... 35 million people in Japan. Mountain Cedar pollen wreaks ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
... QED International Associates, Inc.,administrator for the HealthShares(TM) ... HealthShares(TM) Exchange-Traded Funds, today announced,that effective at the ... Pharmaceuticals Inc. (Nasdaq: REGN ) will replace ... HealthShares(TM) Composite Index. MGI Pharma is being,acquired by ...
... 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,the ... announces that it,has achieved another targeted milestone ... (Canada) Ltd., Dalton Medicinal Chemistry Partners ... and synthesize novel compounds against an,antiviral target ...
Cached Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes 2
(Date:8/21/2014)... Ever heard of the water window? It consists of ... are not absorbed by the water in biological tissues. ... develop coherent radiations within the water window. These could ... a high-contrast image of the biological samples or to ... study identifies the physical mechanism needed to efficiently generate ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... a novel and versatile modeling strategy to simulate polyelectrolyte ... as well as for studying polyelectrolytes, including DNA and ... much larger and more complex polyelectrolyte systems, and to ... author of a paper on the work and a ... and Engineering. "This is a big step forward for ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... European College of Neuropsychopharmacology (ECNP) is pleased to announce ... 2010 ECNP Lifetime Achievement Award in recognition of his ... diseases and neuropsychiatric drug development. The ECNP Lifetime Achievement ... impact on the field of neuropsychopharmacology. The award is ...
... firms and other life science organizations are ... environments and developing more sustainable operations, reports ... (GEN). This promising trend was made clear ... discussions that took place at GEN,s ( ...
... A new study from the Center for Interdisciplinary ... an additional link between Light At Night (LAN) and ... carried out at the University of Haifa that also ... to ,environmental light pollution, which the study has shown ...
Cached Biology News:Moussa B.H. Youdim wins the 2010 ECNP Lifetime Achievement Award 2GEN reports on the greening of the life sciences 2Connection between light at night (LAN) and cancer revealed in additional study 2
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class ... Chemical QA/QC software, Agilents world-renowned support and ... consumables and supplies--a combination that lets you ... decisions based on dependable data. The Agilent ...
... Plus is a small and sensitive ... for both LC and IC. It features ... Pressure Ionization (API) source for outstanding sensitivity ... compatible with existing LC and IC methods, ...
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
Biology Products: